Share on StockTwits

Cell Therapeutics (NASDAQ:CTIC) EVP Matthew Plunkett sold 12,000 shares of the stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $2.48, for a total transaction of $29,760.00. Following the sale, the executive vice president now directly owns 572,904 shares in the company, valued at approximately $1,420,802. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on CTIC. Analysts at WallachBeth Capital upgraded shares of Cell Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. They now have a $4.50 price target on the stock. Analysts at Ladenburg Thalmann initiated coverage on shares of Cell Therapeutics in a research note on Thursday, May 22nd. They set a “buy” rating and a $6.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $4.83.

Shares of Cell Therapeutics (NASDAQ:CTIC) traded up 1.24% during mid-day trading on Wednesday, hitting $2.45. 945,942 shares of the company’s stock traded hands. Cell Therapeutics has a one year low of $1.01 and a one year high of $4.25. The stock has a 50-day moving average of $2.75 and a 200-day moving average of $3.1. The company’s market cap is $367.4 million.

Cell Therapeutics (NASDAQ:CTIC) last announced its earnings results on Monday, August 4th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.07. On average, analysts predict that Cell Therapeutics will post $-0.58 earnings per share for the current fiscal year.

Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.

Receive News & Ratings for Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.